Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 1/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | TEAD1 | P28347 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | RHOC | P08134 | 1/20 | 0.39 |
| ▸ | RHOA | P61586 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242742 | 0.84 | UBE2M (0.46) | UBE2MDCUN1D1EPHX2 | |
| SCHEMBL4247943 | 0.83 | POLB (0.56) | UBE2MDCUN1D1RHOCRHOA | |
| SCHEMBL4238740 | 0.83 | UBE2M (0.41) | UBE2MDCUN1D1EPHX2CCR5 | |
| SCHEMBL4244477 | 0.82 | EPHX2 (0.49) | UBE2MDCUN1D1EPHX2MLNRTEAD1 | |
| SCHEMBL4236028 | 0.81 | ALDH1A1 (0.47) | UBE2MDCUN1D1 | |
| SCHEMBL4240045 | 0.81 | ALDH1A1 (0.47) | UBE2MDCUN1D1 | |
| SCHEMBL4238870 | 0.79 | MAPT (0.56) | — | |
| SCHEMBL4586330 | 0.78 | CARM1 (0.44) | EPHX2MLNRPHGDHCYP2D6KCNH2 | |
| SCHEMBL4245557 | 0.77 | UBE2M (0.48) | UBE2MDCUN1D1EPHX2 | |
| SCHEMBL4240447 | 0.77 | POLB (0.35) | UBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1708703-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2008-04-09 | — | — | EP | disclosed |
| EP-1708703-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-10-11 | — | — | EP | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | UBE2M 4562/4885DCUN1D1 3581/4885EPHX2 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.